Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:HRTX NASDAQ:NGNE NASDAQ:OPTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$15.17-3.9%$11.41$2.60▼$15.94$1.41B-0.331.99 million shs1.64 million shsHRTXHeron Therapeutics$1.30-3.7%$1.30$1.04▼$2.68$247.48M1.251.63 million shs976,159 shsNGNENeurogene$33.99-1.1%$21.03$6.88▼$74.49$490.53M1.58233,068 shs284,748 shsOPTNOptiNose$9.60$9.57$4.82▼$17.18$97.22M-0.8863,682 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+11.28%+17.14%+33.25%+90.70%+300.76%HRTXHeron Therapeutics+2.27%0.00%+8.87%-32.50%-25.00%NGNENeurogene+3.52%+33.06%+96.96%+52.08%-31.22%OPTNOptiNose0.00%0.00%0.00%0.00%-9.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$15.17-3.9%$11.41$2.60▼$15.94$1.41B-0.331.99 million shs1.64 million shsHRTXHeron Therapeutics$1.30-3.7%$1.30$1.04▼$2.68$247.48M1.251.63 million shs976,159 shsNGNENeurogene$33.99-1.1%$21.03$6.88▼$74.49$490.53M1.58233,068 shs284,748 shsOPTNOptiNose$9.60$9.57$4.82▼$17.18$97.22M-0.8863,682 shsN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+11.28%+17.14%+33.25%+90.70%+300.76%HRTXHeron Therapeutics+2.27%0.00%+8.87%-32.50%-25.00%NGNENeurogene+3.52%+33.06%+96.96%+52.08%-31.22%OPTNOptiNose0.00%0.00%0.00%0.00%-9.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 2.86Moderate Buy$15.753.82% UpsideHRTXHeron Therapeutics 2.25Hold$4.50246.15% UpsideNGNENeurogene 2.56Moderate Buy$46.1735.82% UpsideOPTNOptiNose 2.00Hold$9.00-6.25% DownsideCurrent Analyst Ratings BreakdownLatest OPTN, HRTX, AMLX, and NGNE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025AMLXAmylyx PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$10.00 ➝ $19.0010/9/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.0010/8/2025AMLXAmylyx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025NGNENeurogeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/3/2025AMLXAmylyx PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $16.0010/2/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$45.009/27/2025AMLXAmylyx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NGNENeurogeneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M15.48N/AN/A$2.40 per share6.32HRTXHeron Therapeutics$144.29M1.65N/AN/A($0.22) per share-5.91NGNENeurogene$930K521.55N/AN/A$20.89 per share1.63OPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)HRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)NGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)OPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%N/ALatest OPTN, HRTX, AMLX, and NGNE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025HRTXHeron Therapeutics-$0.02N/AN/AN/A$39.03 millionN/A11/6/2025Q3 2025AMLXAmylyx Pharmaceuticals-$0.45N/AN/AN/AN/AN/A8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/A8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.44-$0.46-$0.02-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A8.728.72HRTXHeron TherapeuticsN/A0.820.53NGNENeurogeneN/A18.0718.07OPTNOptiNoseN/A0.790.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%HRTXHeron Therapeutics80.01%NGNENeurogene52.37%OPTNOptiNose85.60%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals12.30%HRTXHeron Therapeutics5.86%NGNENeurogene11.64%OPTNOptiNose2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.17 million78.20 millionOptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableNGNENeurogene9014.27 million12.61 millionOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableOPTN, HRTX, AMLX, and NGNE HeadlinesRecent News About These CompaniesParatek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty TherapiesMay 21, 2025 | finance.yahoo.comOptinose Stockholders Approve Merger with ParatekMay 16, 2025 | tipranks.comOptiNose (OPTN) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNApril 29, 2025 | businesswire.comOptinose Reports 2024 Financial Results, Highlights Prescription Growth and First Operational IncomeMarch 28, 2025 | msn.comOptinose reports Q4 EPS (3c) vs ($1.33) last yearMarch 27, 2025 | markets.businessinsider.comOptinose Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsMarch 26, 2025 | markets.businessinsider.comOptiNose (OPTN) Reports Q4 Loss, Tops Revenue EstimatesMarch 26, 2025 | zacks.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GB, RDFN, PRA, OPTN on Behalf of ShareholdersMarch 25, 2025 | morningstar.comMWall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to TradeMarch 24, 2025 | zacks.comOptinose downgraded to Neutral from Buy at H.C. WainwrightMarch 22, 2025 | markets.businessinsider.comOPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTNMarch 21, 2025 | businesswire.comOPTN Stock Soars 53% on Inking $330M Deal to be Acquired by ParatekMarch 21, 2025 | zacks.comOptinose downgraded to Neutral from Overweight at Piper SandlerMarch 21, 2025 | markets.businessinsider.comOptinose downgraded to Hold from Buy at Lake StreetMarch 21, 2025 | markets.businessinsider.comWhy OptiNose Inc. (OPTN) Surged On Thursday?March 21, 2025 | msn.comLake Street Downgrades OptiNose (OPTN)March 21, 2025 | msn.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of ShareholdersMarch 21, 2025 | globenewswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | gurufocus.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTNMarch 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPTN, HRTX, AMLX, and NGNE Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$15.17 -0.62 (-3.93%) Closing price 04:00 PM EasternExtended Trading$15.61 +0.44 (+2.89%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Heron Therapeutics NASDAQ:HRTX$1.30 -0.05 (-3.70%) Closing price 04:00 PM EasternExtended Trading$1.32 +0.01 (+1.15%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Neurogene NASDAQ:NGNE$33.99 -0.38 (-1.11%) Closing price 04:00 PM EasternExtended Trading$34.04 +0.05 (+0.15%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.OptiNose NASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
